ImageneBio Inc
NASDAQ:IMABiotechnology
Healthcare
$4.61 +6.06%
+$0.35 today
- Market cap
- $52.00M
- Beta
- 0.72
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.02
52W Low $3.94High $18.00
Volume 0.00M
Average 0.35M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$47.84M
FY 2025 · Annual
Investing Cash Flow
-$5.81M
FY 2025 · Annual
Financing Cash Flow
$135.47M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (34.12M) | (68.77M) | (68.17M) | (49.23M) | (52.4M) |
| Depreciation & Amortization | 544K | 751K | 1.02M | 490K | 328K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.18M | 7.53M | 0 | 5.3M | 15.39M |
| Change in Working Capital | (33.03M) | (15.14M) | (21.67M) | (3.98M) | (19.19M) |
| Accounts Receivables | 361K | (291K) | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | (2.87M) | (1.17M) | (2.82M) |
| Other Working Capital | (33.39M) | (14.85M) | (18.8M) | (2.81M) | (16.37M) |
| Other Non-Cash Items | 1.17M | 1.52M | 9.07M | 1.42M | 8.02M |
| Operating Cash Flow | (60.25M) | (74.11M) | (79.74M) | (46M) | (47.84M) |
| Capital Expenditures | (1.76M) | (1.43M) | (414K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (5.22M) |
| Purchases of Investments | 0 | (216.34M) | (90.05M) | (88.3M) | (10.4M) |
| Sales of Investments | 0 | 118.49M | 154.61M | 60.46M | 9.8M |
| Other Investing Activities | 0 | 0 | 0 | (7.07M) | 0 |
| Investing Cash Flow | (1.76M) | (99.28M) | 64.14M | (34.9M) | (5.81M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 15M |
| Common Stock Issued | 131.3M | 0 | 37.56M | 0 | 65.84M |
| Common Stock Repurchased | 0 | 0 | (663K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 582K | 1.1M | 39.09M | 0 | 54.63M |
| Financing Cash Flow | 131.74M | 1.1M | 75.98M | 0 | 135.47M |
| Effect of Forex Changes | 0 | 0 | (406K) | 0 | 604K |
| Net Change in Cash | 69.73M | (172.3M) | 59.98M | (80.91M) | 82.41M |
| Free Cash Flow | (62.01M) | (75.54M) | (80.16M) | (46M) | (47.84M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$52.4M
+ D&A$328.0K
+ Stock-Based Comp$15.4M
+ Deferred Tax$0
- Working Capital-$19.2M
+ Other Non-Cash$8.0M
= Operating Cash Flow-$47.8M
- Capex$0
= Free Cash Flow-$47.8M
Analysis
FY2025 free cash flow is -$47.8M. FCF conversion is 91.3% of net income. Operating cash flow was -$47.8M, with capex of $0. The largest bridge item is Working Capital at -$19.2M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Aug 17, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 17, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| EFFECT | EFFECT filing | Aug 11, 2026 | |
| EFFECT | EFFECT filing | Aug 11, 2026 |
Does IMA generate free cash flow?
ImageneBio Inc (IMA) generated -$47.84M of free cash flow in fiscal 2025.
How much operating cash flow does IMA produce?
Operating cash flow was -$47.84M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.